LIVINGSTON, NJ--(Marketwired - October 10, 2016) - Milestone Scientific, Inc. (NYSE MKT: MLSS), a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies, today announced the expansion of the senior management team with the appointment of James McAvinn as Senior Vice President of Sales & Marketing.
Mr. McAvinn brings over 35 years of experience in the healthcare industry including a variety of senior management, consulting, product management and marketing positions. Most recently, he served as a principal of MRA Consulting, where he served as a strategic advisor to leading pharmaceutical, medical device and OEM suppliers. From 2013 to 2016, he served as Managing Director of Product Management for 3si | Surgical Safety Solutions, where he drove product strategy and execution in global surgical and interventional markets. He has also held senior executive roles at Macquet Cardiovascular, The Nova Group, MD Analytics Group, Boston Scientific Corp., Meadox Medicals, and Baxter Healthcare Corp. He holds four U.S patents for medical and surgical devices. Mr. McAvinn has an MBA from the University of Chicago, an MS in Bioengineering from the University of Illinois, and a BA in Physics from Indiana University.
Leonard Osser, Chief Executive Officer of Milestone Scientific, commented, "We are pleased to announce the appointment of such a highly experienced and proven industry executive. His product strategy, sales and marketing background, as well as his strong leadership skills will be integral to Milestone's next phase of growth. On the heels of completing the clinical trials of our epidural instrument in the United States, we are now moving forward aggressively with the full commercial roll-out of our computer controlled injection system to the global marketplace."
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS) is a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies. Milestone's computer-controlled systems make injections precise, efficient, and virtually painless. For more information please visit our website: www.milestonescientific.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2015. The forward looking-statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.